A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia

Published:2017-08-02 Issue:12 Volume:64 Page:e26651
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Kloos Robin Q.H.¹^ORCID,Uyl-de Groot Carin A.²,van Litsenburg Raphaële R.L.³⁴,Kaspers Gertjan J.L.³⁴,Pieters Rob⁴,van der Sluis Inge M.¹⁴

Affiliation:

1. Pediatric Oncology and Hematology; Erasmus MC-Sophia Children's Hospital; Rotterdam The Netherlands

2. Institute of Health Care Policy and Management/Institute for Medical Technology Assessment; Erasmus University; Rotterdam The Netherlands

3. Department of Pediatric Oncology/Hematology; VU University Medical Center; Amsterdam The Netherlands

4. Princess Máxima Center for Pediatric Oncology; Utrecht The Netherlands

Funder

Stichting Kinderen Kankervrij

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.26651/fullpdf

Reference32 articles.

1. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study;Amylon;Leukemia.,1999

2. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial;Duval;Blood.,2002

3. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia;Moghrabi;Blood.,2007

4. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia;Pession;J Clin Oncol.,2005

5. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study-a report from the Associazione Italiana Ematologia Oncologia Pediatrica;Rizzari;J Clin Oncol.,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Refined Population Pharmacokinetic Model–Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia;Therapeutic Drug Monitoring;2024-08-13

2. Real-World Cost of Pediatric Acute Lymphoblastic Leukemia Care Among Commercially Insured Individuals in the United States: Effect of Era and Age at Diagnosis;JCO Oncology Practice;2022-11

3. Activity and toxicity of intramuscular 1000 iu /m ² polyethylene glycol‐ E. coli L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials;British Journal of Haematology;2022-03-29

4. Asparaginase drugs: a new view of the mechanism of action, side effects and experience in BFM (Berlin–Frankfurt–Munster) protocols;Russian Journal of Pediatric Hematology and Oncology;2022-01-20

5. Comment on: “Premedication prior to PEG‐asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia”;Pediatric Blood & Cancer;2021-12-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3